Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.
Identifieur interne : 001397 ( PubMed/Corpus ); précédent : 001396; suivant : 001398Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.
Auteurs : C. Lepen ; S. Wait ; F. Moutard-Martin ; M. Dujardin ; M. ZiéglerSource :
- PharmacoEconomics [ 1170-7690 ] ; 1999.
English descriptors
- KwdEn :
- MESH :
- geographic : France.
- economics : Parkinson Disease.
- pathology : Parkinson Disease.
- Adult, Costs and Cost Analysis, Disease Progression, Humans.
Abstract
To assess the relationship between severity and progression of illness in Parkinson's disease and the use of healthcare resources.
PubMed: 10539122
Links to Exploration step
pubmed:10539122Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.</title><author><name sortKey="Lepen, C" sort="Lepen, C" uniqKey="Lepen C" first="C" last="Lepen">C. Lepen</name><affiliation><nlm:affiliation>Laboratoire d'Economie et de Gestion des Organismes de Santé (LEGOS), Université Paris Dauphine, France. lepen@clp-sante.fr</nlm:affiliation></affiliation></author><author><name sortKey="Wait, S" sort="Wait, S" uniqKey="Wait S" first="S" last="Wait">S. Wait</name></author><author><name sortKey="Moutard Martin, F" sort="Moutard Martin, F" uniqKey="Moutard Martin F" first="F" last="Moutard-Martin">F. Moutard-Martin</name></author><author><name sortKey="Dujardin, M" sort="Dujardin, M" uniqKey="Dujardin M" first="M" last="Dujardin">M. Dujardin</name></author><author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M" last="Ziégler">M. Ziégler</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10539122</idno><idno type="pmid">10539122</idno><idno type="wicri:Area/PubMed/Corpus">001397</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001397</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.</title><author><name sortKey="Lepen, C" sort="Lepen, C" uniqKey="Lepen C" first="C" last="Lepen">C. Lepen</name><affiliation><nlm:affiliation>Laboratoire d'Economie et de Gestion des Organismes de Santé (LEGOS), Université Paris Dauphine, France. lepen@clp-sante.fr</nlm:affiliation></affiliation></author><author><name sortKey="Wait, S" sort="Wait, S" uniqKey="Wait S" first="S" last="Wait">S. Wait</name></author><author><name sortKey="Moutard Martin, F" sort="Moutard Martin, F" uniqKey="Moutard Martin F" first="F" last="Moutard-Martin">F. Moutard-Martin</name></author><author><name sortKey="Dujardin, M" sort="Dujardin, M" uniqKey="Dujardin M" first="M" last="Dujardin">M. Dujardin</name></author><author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M" last="Ziégler">M. Ziégler</name></author></analytic><series><title level="j">PharmacoEconomics</title><idno type="ISSN">1170-7690</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Costs and Cost Analysis</term><term>Disease Progression</term><term>France</term><term>Humans</term><term>Parkinson Disease (economics)</term><term>Parkinson Disease (pathology)</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Costs and Cost Analysis</term><term>Disease Progression</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To assess the relationship between severity and progression of illness in Parkinson's disease and the use of healthcare resources.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10539122</PMID><DateCreated><Year>1999</Year><Month>08</Month><Day>31</Day></DateCreated><DateCompleted><Year>1999</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1170-7690</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>1999</Year><Month>Jul</Month></PubDate></JournalIssue><Title>PharmacoEconomics</Title><ISOAbbreviation>Pharmacoeconomics</ISOAbbreviation></Journal><ArticleTitle>Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>59-69</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the relationship between severity and progression of illness in Parkinson's disease and the use of healthcare resources.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">This was a prospective cost-of-illness study conducted in France based on clinical observation over a 6-month period of patients with Parkinson's disease treated in the hospital or community setting. Regression analyses were performed to construct the model that offered the best explanation for health expenditures using clinical and sociodemographic indicators.</AbstractText><AbstractText Label="PATIENTS AND PARTICIPANTS" NlmCategory="METHODS">All patients included in the study had well-defined idiopathic Parkinson's disease, were aged > 35 years, were receiving treatment with levodopa or other antiparkinsonian agents, and were capable of completing questionnaires, alone or with the help of a household member. The final study population consisted of 294 patients, of whom 54 were enrolled by general practitioners and 240 by neurologists.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Investigators completed a clinical questionnaire at the beginning and end of the 6-month observation period. Patients completed a questionnaire on their daily living conditions at the beginning and end of the study, and also completed monthly reports of healthcare use and loss of productivity. Patients with motor fluctuations also filled in fluctuation diaries on 4 consecutive days at the beginning and end of the 6-month period. Resource data collected included hospital stays, ancillary care, drug therapy, medical visits and transportation. Social costs were evaluated in nonmonetary terms, with the exception of costs of adapting the home environment. Transfer payments were analysed using reports from patients.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES AND RESULTS" NlmCategory="RESULTS">Hospital stays were the most expensive component of care (39% of costs), followed by ancillary care (30%) and drug therapy (22%). The mean medical cost was 308 euros (EUR) [$US357] for patients followed by a general practitioner and EUR2580 ($US2993) for patients followed by a neurologist. Costs also varied with age and motor fluctuations. Medical costs were strongly correlated with most clinical indicators and the cost generally progressed in line with the severity of the disease. The strongest correlation was between clinical indicators and ancillary care costs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results confirm the importance of the social burden of Parkinson's disease. The regression results could be used to evaluate the benefit of novel treatments that reduce the intensity of motor fluctuations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>LePen</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire d'Economie et de Gestion des Organismes de Santé (LEGOS), Université Paris Dauphine, France. lepen@clp-sante.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wait</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Moutard-Martin</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ziégler</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Pharmacoeconomics</MedlineTA><NlmUniqueID>9212404</NlmUniqueID><ISSNLinking>1170-7690</ISSNLinking></MedlineJournalInfo><CitationSubset>T</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>10</Month><Day>28</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>10</Month><Day>28</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10539122</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001397 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001397 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:10539122
|texte= Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10539122" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |